bluuebunny/crossref_metadata_2025 huggingface dataset:
Association between the changes in walking speed during 6 months after discharge and subsequent prognosis in older patients with heart failure: report from a multicenter prospective cohort study
Authors: Hanada S , Adachi T , Iwatsu K , Kamisaka K , Kamiya K , Yamada S
Published: October 2022

Background

Walking speed (WS) is one of the key components of physical frailty associated with a prognosis in patients with heart failure (HF). However, the prognostic impact of changes in WS after discharge in patients with HF remains to be examined.

Purpose

The purpose of this study was to examined the association between the change in WS during 6 months after discharge and subsequent prognosis in older patients with HF.

Methods

This study was performed as a sub-analysis of the multicenter cohort study in Japan (FLAGSHIP). We analyzed patients hospitalized for HF aged ≥65 years whose WS was measured at discharge and after 6 months of discharge. Based on the patterns of WS at the two points, patients were divided into four groups (A: WS ≥0.98 m/s both at discharge and 6-month; B: ≥0.98 m/s at discharge, <0.98 m/s at 6-month; C: <0.98 m/s at discharge, ≥0.98 m/s at 6-month; D: <0.98 m/s both at discharge and 6-month). WS <0.98 m/s has been identified as a cut-off value predicting the prognosis of HF in the main analysis of the FLAGSHIP. Kruskal - Wallis test was used to compare among groups. Furthermore, Cox proportional hazards model was performed to evaluate the association between the WS subgroups and HF rehospitalization after 6-month of discharge. Additionally, adjustments were made for age and sex in model 1, and for age, sex, cognitive function (Mini-mental state examination, MMSE ≤23), past HF hospitalization, rehospitalization within 6 months after discharge, and variables with a p value <0.05 both at discharge and 6 months in univariate analysis in model 2.

Results

A total of 890 patients were included in this study (Group A: n=386, B: n=51, C: n=143, D: n=310). There was a significant difference in HF rehospitalization after 6-month of discharge among the four groups (Log-rank test, p=0.01, Figure 1). In the crude model, hazard ratio (HR) of group B compared with A was 2.26 [95% confidence interval: 1.19–4.27, p=0.013], HR of C was 1.00 [0.56–1.77, p=0.988], and HR of D was 1.66 [1.11–2.47, p=0.013]. In model 1, HR of B was 2.12 [1.11–4.07, p=0.023], HR of C was 0.99 [0.56–1.75, p=0.964], and HR of D was 1.56 [1.01–2.42, p=0.047]. In model 2, HR of B was 0.95 [0.45–1.97, p=0.897], HR of C was 0.67 [0.35–1.26, p=0.212], and HR of D was [0.25–0.80, p=0.007].

Conclusion

Although slow WS is associated with poor prognosis, the prognosis might be improved if WS increases by 6 months after discharge.

Funding

This study is supported by a Grant-in-Aid for Scientific Research (A) from the Japanese Society for the Promotion of Science [16H01862].

Funding Acknowledgement

Type of funding sources: Public Institution(s). Main funding source(s): The Japanese Society for the Promotion of Science
Cardiovascular rehabilitation delivery and outcomes in Switzerland: data from a national database over the last decade
Authors: Tessitore E , Schmid J P , Hermann M , Capoferri M , Kiencke S , Schmied C , Tschanz H , Wilhelm M , Meyer P
Published: October 2022

Background

Cardiac rehabilitation (CR) is a multidisciplinary, comprehensive, exercise-based intervention strongly recommended by current guidelines to improve symptoms and quality of life and to reduce cardiovascular adverse outcomes, mainly in patients with coronary artery disease and heart failure. CR activities have not been reported on a Swiss national base so far.

Purpose

To report CR outcome variables from a Swiss national base.

Methods

As part of the Swiss working group for cardiovascular prevention, rehabilitation, and sports cardiology (SCPRS) quality standards, all Swiss CR centres provide yearly a quality indicator report on an online questionnaire. Annual data from 2010 to 2019 were transferred as medians or means of all individual patients' data from each centre. We used the t-Student test to compare changes of outcome variables between entry and exit of the programme.

Results

A total of 133,060 CR patients were included (68,690 inpatients and 64,370 outpatients) with a progressive increase reaching its climax with 14'909 patients/year in 2018. Mean age ± standard deviation (SD) in outpatient and inpatient programmes was 60±1 and 68±1 years, and women percentage 21% and 32%, respectively. The most common CR indication was acute coronary syndrome (51%) in outpatient, whereas cardiovascular surgery of various types (60%) was the main indication in inpatient programmes. Mean improvement ± SD of functional capacity was 38% ±3.6 using the six-minute walk test in inpatient (p<0.001) and 21% ±2 using cycle-ergometer maximal exercise testing in outpatient programmes (p<0.001). Quality of life mainly assessed with the 12-item Short Form Survey (SF-12) in outpatient CR improved by 13% ±4.5. MacNew Heart questionnaire systematically performed in inpatient programmes showed significant improvement at emotional level by 12% ±0.4, at physical level by 30% ±0.9, and at social level by 18% ±0.6.

Conclusion

Even if still underutilised in certain groups of patients such as women or heart failure, CR has gained growing importance in Switzerland during the last decade. Functional capacity, as well as quality of life, was significantly improved. Individual CR patient data should be collected in the future to improve assessment of outcome parameters and benchmarking of centres.

Funding Acknowledgement

Type of funding sources: None.
Comparing the findings and diagnostic accuracy of cardiac magnetic resonance imaging in patients with biopsy confirmed acute myocarditis presenting with infarct-like and heart failure symptoms
Authors: Hassan K M , Kyriakakis C G , Doubell A F , Robbertse P P , Joubert L H , Zaharie S D , Van Zyl G U , Herbst P H
Published: October 2022

Introduction

Cardiac magnetic resonance imaging (CMR) is considered the reference imaging modality in providing a non-invasive diagnosis of acute myocarditis (AM), as it allows for the detection of myocardial injury associated with AM. However, the diagnostic accuracy and pattern of CMR findings appear to differ according to clinical presentation.

Methods

This is a retrospective cross-sectional study. Consecutive adult patients presenting to a single tertiary centre in South Africa between August 2017 and November 2021 with endomyocardial biopsy (EMB) confirmed AM presenting with infarct-like (IL) or heart failure (HF) symptoms who had undergone CMR were included.

Results

Thirty-eight patients were enrolled. Twenty-two presented with IL symptoms and sixteen with HF symptoms. On CMR, the IL group had significantly higher ejection fractions of both ventricles (LVEF 54.3±14.9% vs 35.4±14.0%, p<0.001; RVEF 56.8±10.9% vs 43.6±18.6%, p=0.03), despite similar end diastolic dimensions (LVEDVi 83.2±30.9 ml/m2 vs 104.4±38.0 ml/m2, p=0.07; RVEDVi 74.4±22.1 ml/m2 vs 85.8±29.9 ml/m2, 0=0.19). Myocardial oedema was detected more frequently on T2-weighted imaging (90.9% vs 62.5%, p=0.05) and in more myocardial segments (3.0 (IQR 2.0–4.0) vs 1.0 (IQR 0–1.0), p 0.003) in the IL group. Despite no significant difference in the prevalence of late gadolinium enhancement (LGE) between the two groups (95.5% vs 68.8%, p=0.06), the IL group had LGE detectable in significantly more ventricular segments (4.5 (IQR 2.3–6.0) vs 2.0 (IQR 0–3.3), p=0.01) and in a different distribution. The sensitivity of the original Lake Louise Criteria (LLC) was 90.9% in IL patients and 56.3% in HF patients, which improved to 95.5% and 68.8% with the updated LLC respectively.

Conclusion

The pattern of CMR findings and its diagnostic accuracy appears to differ in AM patients presenting with IL and HF symptoms. Although the sensitivity of the LLC improved with the addition of parametric mapping in the HF group, it remained lower than that of the IL group, and suggests that EMB should be strongly considered in patients with clinically suspected AM presenting with HF.

Funding Acknowledgement

Type of funding sources: None.
Effect of early hysterectomy on a risk of incident cardiovascular disease in women: a nationwide population-based cohort study
Authors: Kim B G , Yuk J S , Kim G S , Seo J K , Jin M N , Lee H Y , Seo Y S , Kim M H , Yang S W , Yoon S H , Byun Y S , Kim B O
Published: October 2022

Aim

Women who inevitably underwent surgical hysterectomy before natural menopause may have an earlier increase in hematocrit and storage iron than women who continue menstruation, thereby increasing the risk of cardiovascular disease (CVD) early. We aimed to evaluate the association of women with hysterectomy vs. without hysterectomy before their 50s with the risk of incident CVD.

Methods

This was a retrospective-cohort study, 135,575 women aged 40 to 50 years in 2011–2014 were extracted from the Korean Health Insurance Review and Assessment Service data and after propensity score matching, 55,539 pairs were included in hysterectomy and non-hysterectomy group respectively. The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE), a composite of cardiovascular death, myocardial infarction (MI), stroke, and coronary artery revascularization.

Results

After adjustment for confounding factors, hysterectomy group had an increased risk of MACCE compared with non-hysterectomy group (hazard ratio [HR], 1.25; 95% confidence interval [CI], 1.09–1.44). Regarding individual outcomes, cardiovascular death, MI, and coronary revascularization were comparable between the groups, whereas, the risk of stroke was significantly higher in hysterectomy group than non-hysterectomy group (HR, 1.31; 95% CI, 1.12–1.53). Even after excluding women who underwent oophorectomy, hysterectomy group had a higher risk of MACCE than non-hysterectomy group (HR, 1.24; 95% CI 1.06–1.44).

Conclusions

Early surgical menopause due to hysterectomy, not hormonal menopause, was associated with an increased risk for a composite of CVD, especially stroke. This suggest that the role of “uterus” as well as sex hormones may be important for the sharp increase in the risk of CVD in women after menopause.

Funding Acknowledgement

Type of funding sources: None.
Sex disaggregated analysis of risk factors for adverse outcomes in hypertrophic cardiomyopathy
Authors: Butters A , Arnott C , Sweeting J , Claggett B , Atherton J , Semsarian C , Lakdawala N K , Ho C Y , Ingles J
Published: October 2022

Background

Patient sex has been associated with differences in disease penetrance and clinical expression in HCM. We sought to investigate sex-disaggregated differences in risk factors for adverse outcomes in a large international HCM registry.

Methods

This is a retrospective study of HCM patients from the Sarcomeric Human Cardiomyopathy Registry. Cox proportional hazards models were fit with a sex interaction term to determine significant differences between sexes.

Results

6647 (38% women) probands with HCM were included. After a mean follow-up of 6.4 years from first encounter, women had a higher risk of heart failure (HF) composite (HR 1.77; 95% CI 1.56–1.99, p<0.0001), and death (1.22; 1.03–1.45, p=0.02) compared to men. No sex difference existed for ventricular arrhythmia composite (p=0.2) or atrial fibrillation (p=0.6). Sarcomere positive status (Sarc+) and causative variants in MYBPC3 reduced the risk of the HF composite for women, while for men there was no change in risk (P-heterogeneity=0.016 and <0.0001, respectively). Baseline LVEF <35% and larger LA size increased the risk of the HF composite for both sexes but to a greater magnitude in men (P-heterogeneity=0.0003 and 0.04 respectively) (Figure 1). Sarc+ increased the risk of death in men but not women (P-heterogeneity=0.041). Having the HF composite increased the risk of death by 45% in and 240% in men (P-heterogeneity=0.003) (Figure 2).

Conclusion

There are important sex differences in the risk of heart failure and death in those with HCM, with significant heterogeneity of outcomes based on subgroups defined by genetic and imaging factors.

Funding Acknowledgement

Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): The Sarcomeric Human Cardiomyopathy Registry (SHaRe) is supported by an unrestricted research grant from Bristol Myer Squibb, including funds to individual sites for database support.
Prognostic value of a left atrioventricular coupling index (LACI) in pre- and post-menopausal women. from the multi-ethnic study of atherosclerosis (MESA)
Authors: Pezel T , Michos E D , Varadarajan V , Shabani M , Ambale Venkatesh B , Vaidya D , Kato Y , De Vasconcellos H , Heckbert S , Wu C , Post W , Bluemke D , Allison M A , Lima J
Published: October 2022

Background

Endogenous sex hormones associated with both the left atrial (LA) and left ventricular (LV) structures in peri-menopausal women, but the association of menopause status with left atrioventricular coupling is not well established.

Purpose

To assess the prognostic value of a left atrioventricular coupling index (LACI) in pre- and post-menopausal women without a history of cardiovascular disease (CVD) at baseline in the Multi-Ethnic Study of Atherosclerosis (MESA).

Methods

In women participating in the MESA study, the LACI was measured as the ratio of the left atrial (LA) end-diastolic volume to the left ventricular (LV) end-diastolic volume using cardiovascular magnetic resonance (CMR). Cox proportional hazard models were used to assess the association between the LACI and the outcomes of atrial fibrillation (AF), heart failure (HF), and hard CVD defined by myocardial infarction, resuscitated cardiac arrest, stroke, or coronary heart disease death.

Results

Among the 2,087 women participants (61±10 years), 485 cardiovascular events were observed during the mean follow-up period of 13.2±3.3 years. A higher LACI was independently associated with AF (HR 1.70; 95% CI [1.51–1.90]), HF (HR 1.62; [1.33–1.97]), and hard CVD (HR 1.30; [1.13–1.51], all p<0.001). Adjusted models with the LACI showed significant improvement in model discrimination and reclassification when compared to currently used standard models used to predict the incidence of AF (C-statistic=0.82 vs. 0.79; NRI=0.325; IDI=0.036), HF (C-statistic=0.84 vs. 0.81; NRI=0.571; IDI=0.023), hard CVD (C-statistic=0.78 vs. 0.76; NRI=0.229; IDI=0.012).

Conclusion

In a multi-ethnic population of pre- and post-menopausal women, the LACI is an independent predictor of HF, AF, and hard CVD. In both pre- and post-menopausal women, the LACI has an incremental prognostic value for predicting cardiovascular events over traditional risk factors and sex hormone levels.

ClinicalTrials: gov Identifier: NCT00005487

Funding Acknowledgement

Type of funding sources: None.
Increased risk of atrial fibrillation in patients with uterine fibroids: a nationwide population-based study
Authors: Han S , Choi E K , Han K D , Ahn H J , Kwon S , Lee S R , Oh S
Published: October 2022

Background

Uterine fibroid, the most common benign neoplasm of the uterus, is associated with an elevated risk of cardiovascular disease. The link between incident atrial fibrillation (AF) and the uterine fibroid is unclear because earlier studies focused primarily on the development of atherosclerosis and hypertension. We aimed to investigate the risk of AF in patients with uterine fibroid.

Methods

This is a retrospective cohort study using the Korean National Health Insurance Service database (NHIS). From 2009 to 2012, a total of 2,574,349 women (20 to 40 years old) who underwent general health examinations were included. Diagnosis of uterine fibroids and surgical treatment status was defined by the international classification of diseases, 10th revision codes, and procedural codes from the Korean NHIS. The primary outcome was newly diagnosed AF. The risk of AF according to the uterine fibroids and their surgical treatment status was evaluated using Cox proportional-hazard models.

Results

Of the total population, the mean age was 29.76±4.27 years, and 20,682 (0.8%) were identified to have uterine fibroid. Incident AF was identified in 3,868 patients (61 in the fibroid group, 3,807 in the control group) during a mean follow-up of 7.3±1.1 years. Patients of the uterine fibroid group showed a higher incidence of AF compared to the control group (0.41 and 0.20 per 1000 person-years, respectively, Figure 1). Multivariate Cox-regression analysis presented that uterine fibroid was an independent risk factor of AF: hazard ratio (HR) 1.50, 95% confidence interval (CI) 1.16–1.93, p=0.002. Compared to the control group, uterine fibroid patients who underwent surgical treatment tend to show a lower risk for AF (HR 1.22, 95% CI 0.79–1.90) than patients without surgical treatment (HR 1.69, 95% CI 1.24–2.30), though statistical significance was indeterminate (Figure 2). After propensity score matching, patients of the uterine fibroid group showed higher risk of AF when compared to the control group (HR 1.77, 95% CI 1.32–2.63, p<0.001), which was in line with our main results. The presence of uterine fibroid was consistently associated with higher risk of AF among all subgroups except for the stroke subgroup.

Conclusion

Patients with uterine fibroids are predisposed to an increased risk of AF compared to the control group. Careful monitoring of arrhythmia development would be warranted in patients of uterine fibroid and surgical treatment as it is associated with a modest risk decrement of incident AF.

Funding Acknowledgement

Type of funding sources: None.
Assessment of cardiac involvement in patients recovered from corona virus disease-19 (COVID-19) infection using magnetic resonance imaging
Authors: Florentino M , Javier S , Sawit S , Geron V , De La Rosa J , Quetua P , Rosas N
Published: October 2022

Background

Cardiac sequelae after recovery from COVID-19 infection has not been well-established. Recent studies have used cardiac magnetic resonance (CMR) imaging to assess myocardial involvement or ongoing myocarditis in patients with prior COVID-19 infection.

Objectives

The primary objective of this study was to identify the CMR imaging findings in adult COVID-19 recovered patients.

Methods

This was a single-center retrospective observational cohort study of adult COVID-19 recovered patients who underwent cardiac magnetic resonance imaging. Patient demographics, CMR findings, blood marker results, and treatment received were obtained.

Results

Of the 77 included patients, 42 (54.55%) were male, and the median age was 45 years. Only 6 patients had completely normal scans, making the prevalence of an abnormal CMR 92.21% (95% CI 83.5%–96.5%). All those with an abnormality demonstrated late gadolinium enhancement (LGE), and of these, 64 (90%) had preserved left ventricular ejection fraction (LVEF). Thirty-four patients (44%) had evidence of myocardial edema. Among patients with myocardial edema and LGE, the median numbers of involved segments were 4 (range 1–16) and 7 (range 1–15), respectively. Myocardial edema was most frequently found in the mid inferolateral segment (53%), followed by the basal inferior septum, basal anterior septum, and basal inferolateral segments (each with 41%). Meanwhile, late gadolinium enhancements were most commonly located in the basal inferior septum (75%), mid inferior septum (80%), and basal anterior septum (73%).

Conclusion

Cardiac involvement, particularly edema and late gadolinium enhancement, affecting multiple myocardial segments were observed in a considerable number of patients recovered from COVID-19.

Funding Acknowledgement

Type of funding sources: None.
COVID-19 vaccination in the pediatric age and risk for myocarditis
Authors: Aimo A , Cantinotti M , Panichella G , Clerico A
Published: October 2022

Background

There are some concerns about the cost/benefit ratio of Covid-19 vaccination in children and young adolescents age due to the greater response to immune stimulation. Myocarditis is a feared adverse event (AE).

Methods

On January 4, 2022 we searched the Pubmed and EMBASE datasets for population studies assessing myocarditis events in pediatric subjects, and US nationwide data about COVID-19 vaccinations and AEs.

Results

The studies selected (n=10) were highly heterogeneous, and did not include subjects <12 years. The estimated incidence of myocarditis in the US was 2.80 over 100,000 in fully vaccinated individuals (i.e., receiving two doses of mRNA vaccines or received one dose of a single-dose vaccine) aged 6–17 years. No events were reported <5 years (n=9,985). The incidence of myocarditis was 1.05 over 100,000 in those aged 18–64 years, and 2.75 over 1,000,000 ≥65 years. The incidence of fatal or life-threatening myocarditis was 3.78 over 1,000,000 6–17 years, 1.78 over 1,000,000 18–64 years, and 8.54 over 10,000,000 ≥65 years, with the same order of magnitude than the odds of being struck by lightning. The incidence of COVID-19 myocarditis is 1.33 in 1000 <16 years, i.e., 47.5-fold higher than fully vaccinated individuals.

Conclusions

The reported incidence of myocarditis in subjects aged ≥12 years is slightly higher in males and after the second dose, but extremely low. No case of myocarditis <5 years were reported in the US. In fully vaccinated individuals aged 6–17 years, the estimated incidence of myocarditis was far lower than the risk of COVID-19 myocarditis.

Funding Acknowledgement

Type of funding sources: None.
Cardiovascular autonomic nervous function in 7–12 years old children conceived naturally or by ART with frozen and fresh embryo transfer
Authors: Mizrak I , Lund M A V , Landgrebe A V , Asserhoej L L , Gorm G , Clausen T D , Main K M , Vejlstrup N G , Jensen R B , Pinborg A , Madsen P L
Published: October 2022

Background

Cardiovascular autonomic nervous functions (CANF) exert important homeostatic mechanisms to prevent major arterial blood pressure fluctuations by adjusting heart rate (HR), cardiac contractility, and peripheral vascular tone. Children conceived by assisted reproductive technologies (ART) are at risk of increased carotid intima-media thickness, insulin resistance, arterial stiffness, and hypertension. CANF is impaired in children with obesity and diabetes mellitus, and conductance artery stiffness is documented to influence CANF. CANF may therefore be hypothetized to be impaired in children conceived by ART.

Purpose

This is the first study to investigate whether children conceived by ART have impaired CANF as compared to naturally conceived children.

Method

CANF was studied in 105 singletons aged 7–12 years conceived naturally (NC, N=33) or by ART (frozen embryo transfer (FET, N=34) and fresh embryo transfer (Fresh ET, N=38)). CANF was evaluated with continuous non-invasive hemodynamic measurements (Finapres®) by the HR and blood pressure changes seen relative to rest during active standing, deep breathing and Valsalva, respectively.

Results

The descriptive data showed no difference in CANF measurements between our study groups (Table 1). In the multivariate analysis, only the Valsalva HR-ratio to rest was significantly higher in children conceived by FET as compared to NC children after adjustments for age, sex, BMI and maternal age at delivery (Figure 1). For all meaures, the effect size (Hedges d) ranged from 0.02 to 0.48.

Conclusion

In this study only the Valsalva HR-response between FET and NC groups were statistically significant after adjustment for confounders, and in general effect sizes were small. Our study suggests that children conceived by ART do not have a significantly impaired cardiovascular autonomic nervous function as compared to naturally conceived children.

Funding Acknowledgement

Type of funding sources: Foundation. Main funding source(s): Novo Nordisk Foundation
NOAC in adult congenital heart disease patients: a single-center experience
Authors: Rocha B , Maltes S , Cunha G , Paiva M , Brizido C , Aguiar C , Madeira S , Mendes M
Published: October 2022

Background

Adult Congenital Heart Disease (ACHD) patients at increased risk for thromboembolic events are often treated with oral anticoagulation. While vitamin-K antagonists have been the agent of choice for decades, the use of non-vitamin K oral anticoagulants (NOAC) is increasing. We aimed to assess the safety and effectiveness of NOAC in ACHD patients at our centre.

Methods

This is a single-centre study enrolling all patients with ACHD treated with a NOAC from inception to November 2021. Data was collected using a standardized questionnaire applied to all patients by means of a telephone visit, in parallel with a detailed retrospective chart review. The endpoints of interest included thromboembolic and haemorrhagic events, defined as per the standardized International Society on Thrombosis and Haemostasis (ISTH) scale.

Results

Overall, 36 ACHD patients were enrolled [mean age 53±15 years; female sex – 66.7%; previous stroke – 33.3%; median HAS-BLED and CHA2DS2-VASc score – 1 (1–2) and 3 (2–5), respectively], predominantly with moderate or complex congenital defects (52.7%), of whom 14, 8, 8 and 4 were treated with rivaroxaban, apixaban, edoxaban and dabigatran, respectively. Two-thirds had their first NOAC prescription in the latest 3 years (Figure 1). The most common indication for anticoagulation was atrial fibrillation or flutter (77.8%). Over a median time of 36 (18–63) months on NOAC treatment, there were no patients with thromboembolic events, whilst 13 (36.1%) had a haemorrhagic event – annualized event rate of 12.0 (6.9–24.1%). All bleeding events were minor, most often self-limited gingival haemorrhage or epistaxis (n=7) or menorrhagia (n=3). Nasal cautery was needed to treat recurrent epistaxis in 3 patients, whilst 3 other required oral iron supplementation. The strongest predictor of any haemorrhage was a prior cardiovascular hospitalization (HR 3.88; p=0.027).

Conclusions

The use of NOAC in ACHD patients has been increasing in our centre, with encouraging results. The present findings suggest that NOAC are safe and may be effective for thromboembolic event prevention in heterogeneous forms of ACHD.

Funding Acknowledgement

Type of funding sources: None.
Acute heart failure after non-cardiac surgery: incidence, phenotypes, determinants and outcomes
Authors: Gualandro D M , Puelacher C , Chew M S , Andersson H , Lurati Buse G , Glarner N , Mueller D , Cardozo F A M , Burri K , Mork C , Wussler D , Bolliger D , Osswald S , Caramelli B , Mueller C
Published: October 2022

Background

Primary acute heart failure (AHF) is an established and common cause of hospitalization. AHF may also develop secondarily, e.g. postoperatively (pAHF). Little is known about pAHF.

Purpose

To assess the incidence, phenotypes, determinants and outcomes of pAHF following non-cardiac surgery.

Methods

We prospectively included 9,164 consecutive patients at high cardiovascular risk undergoing 11,262 non-cardiac surgeries. The incidence, phenotypes, determinants and outcome of pAHF, centrally adjudicated by independent cardiologists, was determined. Logistic regression models identified the risk factors for pAHF. Cox regression analysis compared mortality and AHF readmission within 1 year in patients with and without pAHF. External validation was performed using a prospective cohort multicenter study of 1250 patients.

Results

The incidence of pAHF was 2.5% (95% confidence interval [CI] 2.2–2.8%). pAHF most often occurred on postoperative day 2 (median day 4). About half of pAHF (51%) occurred in patients without known HF (de novo pAHF), and 49% in patients with chronic HF. Preserved left ventricular ejection fraction (LVEF) was the dominant phenotype among de novo pAHF (72%), while reduced LVEF was dominant among pAHF in chronic HF (43%). Age, coronary artery disease, peripheral artery disease, diabetes, urgent/emergent surgery, chronic HF, atrial fibrillation, chronic obstructive pulmonary disease, anemia, and chronic myocardial injury were independent predictors of pAHF. Patients with pAHF had significantly higher all-cause mortality (44% vs. 11%, p<0.001) and AHF readmission (15% vs. 2%, p<0.001) within 1 year than patients without pAHF. pAHF was an independent predictor of all-cause mortality (adjusted hazard ratio [aHR] 1.7 [95% CI 1.3–2.2]; P<0.001) and AHF readmission (aHR 2.7 [95% CI 1.7–4.2]; P<0.001) within 1 year. Findings were confirmed in an external validation cohort of 1250 patients, e.g. incidence of pAHF 2.4% (95% CI, 1.6–3.3%).

Conclusions

pAHF frequent developed following non-cardiac surgery, being de novo in about half of cases, and associated with an unacceptable high mortality. Strategies focusing on early detection and treatment of pAHF seem warranted.

Funding Acknowledgement

Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Swiss National Science FoundationSwiss Heart Foundation
Clinical features and short-term prognosis in the very elderly, >90 year-old, patients hospitalized with heart failure. A population-based study (2016–2019)
Authors: Anguita Gamez M , Esteban A , Bonilla J L , Garcia M , Bernal J L , Del Prado N , Fernandez Perez C , Gomez Doblas J J , Perez Villacastin J , Marin F , Elola F J , Anguita Sanchez M
Published: October 2022

Background

Heart failure (HF) is a main health problem in western countries, and a major cause of hospitalizations and death, particularly in older people. Few data are available about clinical features and prognosis of very old patients, those aged 90 or more years.

Purpose

To analyse the clinical features and short-term prognosis (in-hospital mortality and 30-day readmission rate) of patients aged 90 or more years hospitalized with HF in Spain in the last years.

Methods

We conducted a retrospective analysis of patients discharged with an ICD-10 main diagnosis of HF from the Spanish National Health System (SNHS) public hospitals between 2016 and 2019, using as source of data the Minimum Basic Data Set of the SNHS. A comparison of clinical profile, in-hospital mortality and 30-day cardiovascular readmission rate between patients aged 75 to 89 years and those with 90 or more years was performed.

Results

From 2016 to 2019, 354,792 episodes of people older than 74-year and principal diagnosis of HF were included, being 59.2% female. Mean age of the whole population was 85.2±5.5 years, crude in-hospital mortality rate was 12.7% and crude cardiovascular 30-day readmission rate, 11.8%. The very older patients' subgroup (90 or more year-old) comprised 78.777 patients (22.2%). Table 1 shows the differences in clinical features between these patients and those aged 75 to 89 (77.8%). Patients aged 90 or more years were female in a higher proportion and showed a higher prevalence of cognitive impairment and renal failure, but a lower prevalence of most comorbidities (coronary artery revascularization, valve heart disease, cancer, diabetes mellitus, chronic liver disease). The diagnosis of previous myocardial infarction, stroke and systemic hypertension was similar in both groups (Table 1). Crude 30-day cardiovascular readmission rate was slightly but significantly lower in the oldest subgroup (10.9% vs 12%, p<0.001), while crude in-hospital mortality was higher (18.5% vs 11%, p<0.001).

Conclusions

Patients aged 90 or more years represents almost a fourth part of elderly patients hospitalized with HF in Spain within the last years. In general, prevalence of comorbidities and associated heart disease was similar or lower, but in-hospital mortality was twice higher, as compared with less older patients.

Funding Acknowledgement

Type of funding sources: None.
The comorbidity network in older adults with atrial fibrillation: a Danish nationwide cohort study
Authors: Dai L , Triolo F , Cordsen P , Larranaga A C , Petrovic M , Onder G , Lip G Y H , Johnsen S P , Vetrano D L
Published: October 2022

Introduction

Individuals affected by atrial fibrillation (AF) often present with multiple comorbidities that challenge their clinical management and worsen the prognosis. Characterizing the network structure of comorbid chronic conditions in AF patients may provide insights to better tailor medical and care management.

Purpose

To examine and compare the network structure of comorbidities in older people with and without AF.

Methods

Cross-sectional data derived from the Danish National Patient Register (period 2012–2017) were examined. Patients 60+ years old by 1. January 2017 with AF were selected and matched by age and sex to non-AF controls. Chronic conditions coded according to the International Classification of Diseases, 10th revision were retrieved and grouped into 60 clinically relevant disease categories for old age. Network analysis was applied to construct the disease networks and the centrality index of expected influence was measured to estimate the disease interconnectedness in each network. The difference in network structure and disease centrality between AF and non-AF patients was formally assessed through network comparison tests.

Results

A total of 96,117 AF patients (72 years old; 45% women) were identified and matched with 96,117 non-AF controls. The most prevalent chronic conditions in AF were hypertension (55.1%), large bowel diseases (36.4%) and ischemic heart disease (36.0%). A significant difference of global network structure was observed between AF and non-AF patients (p<0.001) (Figure1). Chronic obstructive pulmonary disease, depression, inflammatory arthropathy, chronic kidney disease and peripheral neuropathy had a higher connectivity with other diseases in the AF vs. non-AF patients (p<0.001). By contrast, hypertension, heart failure and stroke were more interconnected in the non-AF patients (p<0.001). Among AF patients, network differences were further observed between age categories (60–79 vs 80+ years) in male and female subgroups.

Conclusions

Older AF patients exhibited a complex network structure of chronic conditions that differed from age- and sex- matched non-AF patients. The network-based identification of highly co-morbid diseases in AF can improve our understanding of AF-related chronic conditions and potentially enhance prioritization and a personalized care for older patients with AF.

Funding Acknowledgement

Type of funding sources: Public grant(s) – EU funding. Main funding source(s): European Union's Horizon 2020 research and innovation programme
Prognostic value of cardiac magnetic resonance in elderly patients soon after ST-segment elevation myocardial infarction
Authors: Marcos Garces V , Gabaldon-Perez A , Gavara J , Lopez-Lereu M P , Monmeneu J V , Perez N , Rios-Navarro C , De Dios E , Merenciano-Gonzalez H , Chorro F J , Valente F , Lorenzatti D , Ortiz-Perez J T , Rodriguez-Palomares J F , Bodi V
Published: October 2022

Background

Elderly patients with ST-segment elevation myocardial infarction (STEMI) represent a very high-risk population. Data on the prognostic value of cardiac magnetic resonance (CMR) in this scenario are scarce.

Purpose

We aim to study the prognostic value of an early (1-week) CMR in elderly patients after STEMI and to create a simple risk score including clinical and CMR variables.

Methods

The registry comprised 247 patients over 70 years of age discharged for a first STEMI treated with percutaneous intervention and included in a multicenter registry. Baseline characteristics, echocardiographic parameters and CMR-derived left ventricular ejection fraction (LVEF, %), infarct size (% of left ventricular mass) and microvascular obstruction (MVO, number of segments) were prospectively collected. The additional prognostic power of CMR was assessed using adjusted C-statistic, net reclassification index (NRI) and integrated discrimination improvement index (IDI).

Results

During a 4.8-year mean follow-up, 66 (26.7%) first major adverse cardiac events (MACE) occurred (27 all-cause deaths and 39 re-admissions for acute heart failure). Higher GRACE score (HR 1.03 [1.02–1.04], p<0.001), more depressed CMR-LVEF (HR 0.97 [0.95–0.99] per increased %, p=0.006) and more extensive MVO (HR 1.24 [1.09–1.4] per segment, p=0.001) predicted MACE occurrence. The addition of CMR data significantly improved MACE prediction compared to the model with baseline and echocardiographic characteristics (C-statistic 0.759 [0.694–0.824] vs. 0.685 [0.613–0.756], NRI=0.6, IDI=0.08, p<0.001). The best cut-offs for independent variables were GRACE score >155, LVEF <40%, and MVO ≥2 segments. A simple score (0, 1, 2, and 3) based on the number of altered factors accurately predicted the MACE per 100 person-years: 0.78, 5.53, 11.51 and 78.79, respectively (p<0.001).

Conclusions

CMR data contribute valuable prognostic information in elderly patients submitted to undergo CMR soon after STEMI.

Funding Acknowledgement

Type of funding sources: Public grant(s) – EU funding. Main funding source(s): Instituto de Salud Carlos III and “Fondos Europeos de Desarrollo Regional FEDER” and Conselleria de Educaciόn – Generalitat Valenciana.
Acute coronary syndromes in the elderly: prognostic impact of anaemia
Authors: Morgado Gomes A R , Saleiro D , Campos D , Gameiro J P , Sousa J P , Antonio N S C , Goncalves L
Published: October 2022

Introduction

The increase in life expectancy is a reality and cardiovascular disease incidence rises with it. The elderly are fragile patients with high prevalence of multiple comorbidities. Anaemia is one of them and, in most cases, has multifactorial causes. After an acute coronary syndrome (ACS), the thrombotic versus haemorrhagic risks in these patients are hard to balance.

Aim

The aim of this study is to evaluate prognostic impact of anaemia in the elderly after an ACS.

Methods

Retrospective analysis of consecutive patients admitted to a single Intensive Coronary Unit between 2009 and 2016 with the diagnosis of ACS. Patients younger than 80 years old were excluded. A complete blood count was collected upon admission and anaemia was defined for haemoglobin values below 12.5mg/dL. Cox regression analysis and Kaplan-Meyer curves were conducted to determine prognostic value of anaemia in this specific population. Multivariate analysis with other comorbidities and antithrombotic therapy was also performed.

Results

A total of 353 patients (median age of 84.0±6.0 years old; 52.1% males; 51.3% with anaemia) were enrolled. In cox regression analysis, anaemia predicted mortality (HR 1.614; 95% CI 1.199–2.172; P=0.002). In multivariate analysis – including gender, presence of hypertension, diabetes, chronic kidney disease and atrial fibrillation (AF) at admission, anaemia proved to be an independent predictor of mortality (HR 1.521, 95% CI 1.119–2.069, P=0.007). Adding all previous and discharge antithrombotic therapy – antiplatelet inhibition and oral anticoagulants – to the equation, anaemia maintained its prognostic value (HR 2.157; 95% CI 1.130–4.116; P=0.020). Both AF and being discharged from the hospital with ticagrelor also increased mortality risk in these patients (HR 2.188, 95% CI 1.177–4.070, P=0.13 for AF; HR 1.906, 05% CI 1.011–3.594, P=0.046 for ticagrelor at discharge).

Conclusions

After an ACS, anaemia proved to be an independent predictor of mortality in the elderly. This emphasizes the importance of its adequate aetiology investigation and treatment and careful selection of antithrombotic therapy following an ACS.

Funding Acknowledgement

Type of funding sources: None.
Long-term cardiovascular outcomes in five-year cancer survivors: a nationwide cohort study
Authors: Sun G , Petrie M , Lang N N , McMurray J J V , Jhund P S , Cheng L L , Schou M , Torp-Pedersen C , Fosboel E L , Koeber L , Butt J H
Published: October 2022

Background

Patients with cancer have higher short-term rates of cardiovascular events than the general population. However, little is known about rates of long-term cardiovascular outcomes in 5-year cancer survivors, especially in older patients.

Objective

We investigated the long-term rates of cardiovascular outcomes, including heart failure, atrial fibrillation, venous thromboembolism, ischemic stroke and myocardial infarction in five-year cancer survivors, overall and according to age.

Methods

Using Danish nationwide registries, five-year survivors of 20 of the most common cancers (diagnosed between 1994 and 2013; 15 years of age or older at the time of the diagnosis) were matched with four non-cancer controls from the background population by age and sex. Study participants with a history of any the outcomes of interest prior to index date were excluded. Rates of outcomes in the cancer and non-cancer group were compared with Cox regression models, overall and according to age (i.e., 15–39, 40–59, and >60 years).

Results

In total, 167,215 five-year cancer survivors were age- and sex-matched with 668,860 non-cancer controls (median age 66 years; 34.4% men, median follow-up of 6.8 years). Five-year survivors had higher associated rates of cardiovascular outcomes, irrespective of age, and the incidence rates per 1,000 person-years of cardiovascular outcomes for cancer survivors and non-cancer controls were: HF: 6.2 (95% CI: 6.1–6.4) and 5.2 (5.1–5.3), respectively; atrial fibrillation: 11.1 (10.9–11.3) and 9.3 (9.3–9.4), respectively; venous thromboembolism: 5.1 (5.0–5.2) and 2.8 (2.8–2.9), respectively; ischemic stroke: 5.8 (5.6–5.9) and 5.4 (5.4–5.5), respectively; and myocardial infarction: 3.6 (3.5–3.7) and 3.4 (3.3–3.4), respectively. The absolute rates of cardiovascular outcomes were highest in the oldest group, whereas the relative rates were more pronounced in the youngest cancer group compared with matched controls (Figure 1).

Conclusions

Compared with the general population, five-year cancer survivors had higher associated rates of cardiovascular outcomes across the spectrum of age. The increased rates of cardiovascular outcomes were more pronounced in the youngest group. These data underline the importance of risk assessment and prevention of cardiovascular diseases in five-year cancer survivors.

Funding Acknowledgement

Type of funding sources: None.
Cardiac magnetic resonance imaging predictors of ventricular arrhythmia in mid-cavity obstructive hypertrophic cardiomyopathy
Authors: Malcolmson J W , Hughes R K , Shiwani H , Husselbury T , Procter W , Godec T , Davies R , Omahony C , Moon J , Dhinoja M B , Petersen S E , Mohiddin S A
Published: October 2022

Background/Introduction

Left ventricular (LV) mid-cavity obstruction (LVMCO) in hypertrophic cardiomyopathy (HCM) is an uncommon phenotypic feature predisposed to the formation of myocardial fibrosis and apical aneurysms (LVAA). These features may be independently proarrhythmic, and LVAA is considered a class 2a indication for implantable cardioverter defibrillator (ICD) in current US, but not European guidelines for the primary prevention of sudden cardiac death (SCD). Cardiac magnetic resonance (CMR) imaging is the preferred modality for detecting these and other phenotypic features critical to SCD risk assessment.

Purpose

To assess the ability of CMR imaging parameters to predict occurrence of non-sustained ventricular tachycardia (NSVT) in HCM patients with Doppler-derived evidence of LVMCO.

Methods

Multi-modality imaging records were retrospectively assessed to identify HCM patients with Doppler-LVMCO and CMR scans. CMR images were assessed by an investigator blinded to clinical status. Late gadolinium enhancement (LGE) was quantified using the full-width, half-maximum technique. CMR imaging parameters were assessed for predictive ability using Cox proportional hazards during univariate and multivariate analyses, accounting for time to event (NSVT or censorship of follow-up).

Results

The study cohort included 58 patients (57±11 years, 74% male) with a median follow-up of 6.2 (IQR 4.3) years. Mean mid-cavity gradient was 33±23 mmHg. NSVT was detected in 27/58 (47%) patients, was 4 beats or longer in 23/27 (85%) and was monomorphic in 21/27 (77%).

On univariate analysis, predictors of NSVT during follow-up include LV mass index (HR 1.02, 95% CI 1.00–1.04, p=0.03), LGE in grams (HR 1.04, 95% CI 1.01–1.06, p=0.005), and LVAA (HR 2.57, 95% CI 1.14–5.79, p=0.023). After multivariate adjustment (Table 2), none were significantly associated.

Conclusions

In LVMCO, magnitude of LV hypertrophy, extent of LGE and the presence of an apical aneurysm may not be independent predictors of ventricular arrhythmias. SCD algorithms based on qualitative assessments of these features may overestimate risk.

Funding Acknowledgement

Type of funding sources: Public Institution(s). Main funding source(s): National Institute of Health Research (NIHR)
Cardioprotection against cardiac dysfunction from breast cancer chemotherapy: a bayesian and frequentist network meta-analysis of randomised controlled trials
Authors: Jeyaprakash P , Sangha S , Low G , Yu C , Pathan F , Negishi K
Published: October 2022

Background

Anthracyclines (ANT) are the cornerstone of multiple chemotherapy regimens but at the risk of potential cardiotoxicity. Previous RCTs have tested the prophylactic effects of multiple cardioprotective agents to prevent ANT-related cardiotoxicity. Unfortunately, attempts to combine RCT findings in previous meta-analyses have been heterogeneous, creating further uncertainty. There remains an unmet need to determine the role of cardio-protective agents in breast cancer.

Purpose

To assess the comparative efficacy of cardioprotective drugs in patients with breast cancer using both Bayesian and frequentist analyses of randomised controlled trials

Methods

We performed a systematic review using four databases (CENTRAL, Cochrane Reviews, MEDLINE, SCOPUS), to find RCTs evaluating cardio protective drugs in breast cancer patients without prior ANT exposure. The population included was anthracycline naïve, and trials were excluded if cardio-protective agents were commenced post anthracycline treatment. The primary outcome was a mean change in LVEF pre and post ANT dosing. Results were pooled with both Bayesian and frequentist approaches using random effects models in R statistical software.

Results

We identified 12 RCTs from 2807 search results (n=1126, Age 51 years, ANT dose 412m/m2, baseline LVEF 62.6%) with comparisons including beta-blockers (BB) (n=9), Angiotensin Converting Enzyme inhibitors (ACEi)/Angiotensin Receptor Blockers (ARB) (n=3), combination BB + AA (n=2), spironolactone (n=1) and statins (n=1). All included trials had either intermediate or high risk of bias, with marked heterogeneity in ANT dosing and LVEF monitoring. Overall, our Bayesian network meta-analysis showed no statistically significant difference in mean LVEF preservation between AA (1.3%, 95% credible interval [−0.20, 2.9]), BB (0.77, [−0.21, 1.8]), AABB (0.84 [−1.1, 2.8]), SPR (0.72, [−2.3, 3.7]) or statin (0.60, [−2.4, 3.6]) when compared against placebo. After ranking for efficacy, ACEi/ARBs achieved the most protection against LVEF decline of 1.3% [95% CI: −0.2, 2.9] although still not significant. Conversely, frequentist analysis showed benefit in using AA (Standardised Mean Difference (SMD) 1.32% [0.32, 2.33]) and BB (SMD 0.76% [0.12, 1.4]).

Conclusion

Bayesian analysis demonstrated no difference in LVEF with cardio-protective agents. In contrast, frequentist analysis showed that AA and BB may provide significant cardio-protection. The quality of RCT data to date is limited by a high risk of bias and significant heterogeneity between RCA reporting. Larger trials with clear population definition are required to determine whether any drug class provides benefit in this setting.

Funding Acknowledgement

Type of funding sources: None.